Perceptic, a London-based startup founded by ex-Palantir engineers, has closed a $12 million seed round led by Accel to build what it calls an AI operating system for drug discovery. The company aims to replace the maze of disconnected tools that slow candidate identification and clinical progression with a single, shared intelligence layer.
Perceptic Secures $12M to Unify AI Drug Discovery
The funding positions Perceptic at the center of a fast-growing AI in drug discovery market. Backed by Accel, the team leverages experience building large-scale data platforms to tackle the long, costly path from discovery to approved therapy. The startup intends to link scouting, scientific evaluation, and clinical datasets through interoperable AI services.
Tackling Fragmentation in Pharma R&D
Pharmaceutical R&D is fragmented across specialist databases, lab notebooks, and siloed clinical records. This fragmentation drives repeated work, slow decision cycles, and expensive failures during later-stage development. AI adoption has surged, but most vendors focus on isolated steps such as target identification or molecule design rather than the full lifecycle.
A Holistic AI Approach for Drug Development
Perceptic’s platform acts as connective tissue. Its shared intelligence layer runs AI agents that harmonize diverse data types, extract and standardize scientific evidence, and automate portions of due diligence. Early users report faster portfolio triage and more complete data capture from public and proprietary sources, reducing manual extraction time and speeding go-no-go decisions.
Accelerating Medical Innovation
By connecting the discovery and clinical phases, Perceptic aims to shorten timelines and lower costs, which can translate to earlier patient access to new therapies. Unlike single-stage players such as Insilico Medicine or Isomorphic Labs, Perceptic focuses on integration across the pipeline. Investor support from Accel reflects confidence in a consolidation trend where platforms that unify workflows may reshape how drug projects move from concept to clinic.
For pharma and biotech leaders, Perceptic represents a strategic move toward platform-based AI that helps teams work from a single, intelligent source of truth across the drug lifecycle.
